Additionally, the fact that Navoximod has already been successfully used in our group for cancer therapy also added to the confidence in our decision to choose Navoximod over other IDO-1 inhibitors for the HSV-1 combinatorial virotherapy33. This evidence concerns the gene IDO1 and cancer.